Sorted By:

Relevance


Mental Health Medicines in Development Report, 2014

PhRMA  |  Report

Mental health conditions exact a heavy human and economic toll in the United States. The National Institute of Mental Health (NIMH) estimates that 1 in 4 American adults—61.5 million—have been diagnosed with a mental health disorder. According to the NIMH, serious mental illnesses cost the United...
https://www.phrma.org/report/mental-health-medicines-in-development-report-2014

White House Healthcare Summit Offers Opportunity for Input into Reform

PhRMA  |  Press Release

Industry-wide research and investment reached a record $65.2 billion in 2008.
https://www.phrma.org/press-release/white-house-healthcare-summit-offers-opportunity-for-input-into-reform

Stakeholders raise concerns about ICER’s evidence report for non-small cell lung cancer

PhRMA  |  Blog Post

A key example would be the non-use of figure legends to explain the derivation of the figures throughout the report.
http://catalyst.phrma.org/stakeholders-raise-concerns-about-icers-evidence-report-for-non-small-cell-lung-cancer

PhRMA Statement on Healthcare Reform Coalition

PhRMA  |  Press Release

Industry-wide research and investment reached a record $65.2 billion in 2008.
https://www.phrma.org/press-release/phrma-statement-on-healthcare-reform-coalition

Tackling Impediments to Trade

PhRMA  |  Report

The vast majority of the world’s medical innovation occurs in the United States because of a reliable patent system where risk is rewarded, innovators are protected, and a predictable flow of resources fuels continuous research and development. In 2015, America’s biopharmaceutical sector invested...
https://www.phrma.org/report/tackling-impediments-to-trade

National Cover the Uninsured Week Another Impetus for Action on Healthcare Reform

PhRMA  |  Press Release

Industry-wide research and investment reached a record $65.2 billion in 2008.
https://www.phrma.org/press-release/national-cover-the-uninsured-week-another-impetus-for-action-on-healthcare-reform

PhRMA Statement Regarding AARP Rx Price Watch Report

PhRMA  |  Press Release

The report overemphasizes the impact of specialty medicines, which are used by a small number of beneficiaries and account for a small share of Medicare spending.
https://www.phrma.org/press-release/phrma-statement-regarding-aarp-rx-price-watch-report

Statement on Global IP Agenda: 2009 Special 301 Report

PhRMA  |  Press Release

Industry-wide research and investment reached a record $65.2 billion in 2008.
https://www.phrma.org/press-release/phrma-statement-on-global-intellectual-property-agenda-2009-special-301-report

New report highlights impact of intellectual property on U.S. economy

PhRMA  |  Blog Post

A report by NDP Analytics found that between 2000 and 2010, R&D investment in the pharmaceutical manufacturing industry accounted for 27% of all R&D investment among IP-intensive industries.
http://catalyst.phrma.org/new-report-highlights-impact-of-intellectual-property-on-u.s.-economy

Medicines in Development for Rare Diseases 2016 Report

PhRMA  |  Report

Rare diseases, when taken together, are not that rare at all. In fact, 30 million Americans, or 10 percent of the population, have one of the 7,000 known rare diseases, of which 80 percent are genetic in origin. Half of those affected worldwide are children. A disease is generally defined as “rar...
https://www.phrma.org/report/medicines-in-development-for-rare-diseases-2016-report

Medicines in Development for Autoimmune Diseases 2016 Report

PhRMA  |  Report

View the Full Report  
https://www.phrma.org/report/medicines-in-development-for-autoimmune-diseases-2016-report

New Report: Decades of Drug Research Failures and Successes Transform Hepatitis C from Incurable to Curable Disease

PhRMA  |  Press Release

View the full “Twenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones” report.
https://www.phrma.org/press-release/new-report-decades-of-drug-research-failures-and-successes-transform-hepatitis-c-from-incurable-to-curable-disease

New report: Decade of breakthroughs in cancer

PhRMA  |  Blog Post

Here are some highlights from the report: Melanoma: A wave of immunotherapies has transformed the treatment of the metastatic disease.
http://catalyst.phrma.org/new-report-decade-of-breakthroughs-in-cancer

Panel Discussion and New Report Highlight Benefit of Vermont Clinical Trials for Patients, State Economy

PhRMA  |  Press Release

"Greater awareness and understanding about clinical trials would allow them to explore participating in the research, and the new report provides a helpful step for getting more information about Vermont’s active trials." 
https://www.phrma.org/press-release/panel-discussion-and-new-report-highlight-benefit-of-vermont-clinical-trials-for-patients-state-economy

New Report Shows Minnesota Clinical Trials Benefit Patients, State Economy and Science

PhRMA  |  Press Release

For more information on the "Research in Your Backyard" report, including locations of Minnesota clinical trials, click here.     
https://www.phrma.org/press-release/new-report-shows-minnesota-clinical-trials-benefit-patients-state-economy-and-science

PhRMA and Epilepsy Foundation Report More Than 400 Medicines in Development to Treat Neurological Disorders

PhRMA  |  Press Release

The new report, “Medicines in Development for Neurological Disorders,” demonstrates how the newest advancements seek to treat the underlying mechanisms of neurological disorders.
https://www.phrma.org/press-release/phrma-and-epilepsy-foundation-report-more-than-400-medicines-in-development-to-treat-neurological-disorders

Medicines in Development for Leukemia & Lymphoma 2015 Report

PhRMA  |  Report

Each year, more than 162,000 Americans are diagnosed with a blood cancer—accounting for more than 9 percent of all new cancer diagnoses. Major types of blood cancers include leukemia, lymphoma and myeloma....
https://www.phrma.org/report/medicines-in-development-for-leukemia-and-lymphoma-2015-report

Value-Based Contracting for Oncology Drugs: A NEHI White Paper

PhRMA  |  Report

While new partnerships are developing between insurers and biopharmaceutical companies to increase patients’ access to medicines, outdated regulations prevent insurers from negotiating deals that lower the price of medicines when they are used in combinations or when they don’t deliver the promis...
https://www.phrma.org/report/value-based-contracting-for-oncology-drugs-a-nehi-white-paper

Medicines in Development for Older Americans 2013 Report

PhRMA  |  Report

This report lists medicines and vaccines in human clinical trials or under review by the U.S.
https://www.phrma.org/report/medicines-in-development-for-older-americans-2013-report

ITIF report shows how Canada’s IP system is falling behind

PhRMA  |  Blog Post

As the report states, “Without sufficient IP protections, innovators will have little motivation to invest the economic resources necessary to discover new pharmaceutical compounds.
http://catalyst.phrma.org/itif-report-shows-how-canadas-ip-system-is-falling-behind

PhRMA Statement on Institute of Medicine Report

PhRMA  |  Press Release

Industry-wide research and investment reached a record $65.2 billion in 2008.
https://www.phrma.org/press-release/phrma-statement-on-institute-of-medicine-report

PhRMA and Lupus Foundation of America Report More Than 300 Medicines in Development for Autoimmune Diseases

PhRMA  |  Press Release

View "Medicines in Development for Autoimmune Diseases" here.
https://www.phrma.org

New Report Highlights a Decade of Innovation in Rare Diseases

PhRMA  |  Blog Post

A new report, A Decade of Innovation in Rare Diseases, highlights advances made in the last ten years against a variety of rare diseases, providing new treatments for patients who need them.
http://catalyst.phrma.org/new-report-highlights-a-decade-of-innovation-in-rare-diseases

Supporting Better Patient Outcomes Through Reform

PhRMA  |  Blog Post

Five ‘building blocks’ could help ensure that the HHS’ initiative achieves better outcomes for all patients, including: incorporating clear mechanisms for recognizing new treatment advances, including personalized medicines; expanding the foundation of quality and patient-reported outcomes measures in alternative payment models; promoting informed patient decision-making from the range of available tests and treatment options; taking a holistic, system-wide view of cost and quality; and creating mechanisms for broader stakeholder input in development and evaluation of new payment models.
http://catalyst.phrma.org/supporting-better-patient-outcomes-through-reform

PhRMA Statement on PCAST Innovation Report

PhRMA  |  Press Release

“This report couldn’t have come at a better time andwe look forward to having discussions with members of the new Congress and the Administration on steps we can take to help ensure the U.S. remains the world leader in medical innovation.”
https://www.phrma.org/press-release/phrma-statement-on-pcast-innovation-report

You have reviewed the first 150 results out of 1032. Each page contains 25 results. You're on page 6.

prev 1 2 3 4 5 6 next